The simple term, carcinogen, is used much too loosely by both the general public and a number of scientists. When appropriate, for clarification the designation should be experimental carcinogen. Unfortunately, the mass media often give the wrong impression when potential cancer-causing agents are reported; confusion exists because a report in the mass media that an agent induces a cancer in experimental animals is immediately extrapolated in the minds of many that this agent will produce cancer at once in the general public.
INTRODUCTION
The question of what chemical constitutes a human carcinogen is most complex, and cannot be answered simplistically.
For every complex question, there is almost certainly a simple answer that is almost always wrong.
H.L. Mencken
As quoted by I. Bernard Weinstein
As quoted by A. Furst The problem is that a number of scientists, and especially the lay public, use words much too glibly and too loosely; a carcinogen: is that term related to induction of a tumor in animals? Has it been shown to cause cancer in humans? Are there real data to back up the statement that the substance is a carcinogen, or is that conclusion drawn by inference or analogy?
Confounding the problem is a definition of a carcinogen, proposed by Zwickey and Davis in 1959'*) and accepted today by Huff et al. , (3) to wit: "carcinogens are those substances which produce a significant increase in tumor incidence when administered at any dosage level, by any route of administration in any species of animals compared to controls" [emphasis by A.F.].
The main problem with accepting this definition is that tumor makes no distinction between benign or malignant tumors; any dose level does not consider what human exposure can be; any route may include some that have no relevance to human experience; and any species may include exotic ones like Drosphila or snails.
In a discussion of induction of cancer, the meaning of curcinogenesis runs the entire spectrum: from the Lewis Carroll philosophy to dispassionate science. Higgin~on'~) has wrestled with the problems encountered because of the simplistic definitions of a carcinogen. He prefers the terms "carcinogenic factor" or "carcinogenic stimulus" which will describe any agent, chemical or virus, or life-style risk factor that is associated with an increase of cancer in animals or human^.'^'
The problem would be less confusing if the term "experimental carcinogen" were used to describe the positive result of a bioassay. This is in agreement with Weisburger. (6' 
PUBLIC'S INFORMATION ON CANCER
Where do most people get their information about cancer and chemicals that can potentially cause cancer? First and foremost, through the mass media, mainly newspapers, otherwise via radio or television broadcasts. According to the media in the last few years, designated carcinogens include those listed in Table 1 . Such lists often reflect the general public's perception of the "cancer threat" to themselves. As we continue to read the lay press, we find other causes of cancer (Table 2) . Many states are now setting up special commissions to identify "carcinogens" (without defining the terms) to which the public is exposed. Without adequate guidelines from their advisors, some states have adopted ayes or no philosophy; a substance is carcinogenic or it is not.
A very recent example is that, under Proposition 65 of the State of California, typewriter correction fluid is designated a carcinogen [the standard size bottle contains perhaps one milliliter or so of either 1,4 dioxane or trichloroethylene (TCE)]. The advertisement for the recall of these bottles contains the statement, "These chemicals are known to the State of California to cause cancer."
When we turn to some scientific reviews, we learn that there are many natural products which may cause cancer (Table 3 ). In general, an evaluation of the quality of the reason which led to these conclusions is missing. More information comes from publications of the Japanese scientists (Table 4) .
ON CANCER AND CARCINOGENS
If one looks at the Interagency Committee's recommendations for determining if an agent is a carcinogen (Fed. R e g . , 1984,'15' and U.S. Interagency Staff Group on Carcinogens, 1986,"" Shubik,"" the recommendation that the decision should be based on information from epidemiological studies and on the results from the studies of two animal species seems, on the surface, a reasonable approach. Such a decision would be strengthened if some short-term tests were also positive. In any case, critical evaluations must be made on the various sections of the recommendations. 
ON EPIDEMIOLOGY
MacMahon('*) addressed the questions of the strengths and limitations of epidemiology, but did not deal with association versus cause. He noted that the strength of epidemiology is that the science deals with observations in humans. And there are many such; humans house and feed themselves, keep themselves clean without cost to the investigator. But there are limitations to epidemiological studies, mainly because they are observational, and the lack of knowledge of the other factors which may be distributed in the study population which can affect the disease distribution. His concern about the lack of centralized records can be alleviated somewhat with the organization of government computer data banks.
With its inherent limitations, what should constitute a good study? The Advisory Committee for the U.S. Surgeon General's (SG)(I9) first publication on Smoking and Health adopted a set of criteria for acceptable epidemiological studies of chronic disease. These are:
I . The consistency of the association 2. The strength of the association 3. The specificity of the association 4. The temporal relationship of the association 5. The coherence of the association Although it does state that statistical methods cannot establish proof of a causal relationship, the report does imply a connection between epidemiological association and causation. As such it ignored the criticism of Sir Bradford who in his Presidential Address to the Royal Society of Medicine, January 14, 1965, reminded the audience that association rather than causation was the end result of an epidemiology study. Occasionally, the Surgeon General's report is used as a basis of the claim by some that an epidemiological study can establish cause. Metzger et al.(2') again remind us emphatically, "It must be emphasized that the finding of a correlation does not prove or even imply cause."
However, statements persist in some literature that from epidemiological studies it is indeed possible to conclude causation if the following conditions are met:
1,
2. Strength of association 3. Presence of a dose-response 4. Plausible biological mechanism 5. Consistency of association 6.
Postulated cause precedes the effect Intervention will change the outcome in the direction expected (Note that many of these are subjective, i.e., 2,4,5.) There are three different approaches to epidemiological studies: ( I ) cross-sectional, usually a prevalence study, (2) longitudinal, these can be full cohort, or case-control studies, or (3) interventional and clinical trials.
There does not seem to be enough information, to this observer, on the comparative usefulness of these various studies. Questions can be asked, must corroboration of a conclusion from one type of study come from the same type, or can another type also be used to strengthen the association?
The first SG's report does not address what constitutes a valid study. Much is taken for granted; it is assumed that the data, generated by a study which is analyzed by good statistical and mathematical methods, are free of flaws.
Yerushalmy (22' was one of the first to raise the question whether conclusions inferred from the evidence are scientifically valid. He also raises the question about the bias of selection of the population under study; and, finally, he notes that specificity of association can help the relationship to causation if the characteristic under study is associated with only one, or at best, a very few diseases; the argument is weakened if the characteristic is associated with a number of diseases. Bias may enter in the misclassification of the populations, those associated with the disease or the cohorts,'23) or even in the misclassification of the agent of exposure. Lynch et found the association of drinking chlorinated water with bladder cancer spurious, because the concentration of the chlorine in the water was not correct. Working in: textile factory$38) petrochemical industry:") dye manufacturing;c"6) aluminum reduction plant$40) barber shop;"') butcher shop.'4')
The criteria of a valid epidemiological report and the setting of scientific standards for these studies were most recently addressed by Feinstein.'") He called attention to the fact that there can be hidden biases in the studies such as selection, observation, and other confounding factors. He stated that for some studies the hypothesis was not clearly stated before the research was initiated, and was enunciated only after a correlation was found. He also questioned how many scientists look at autopsy reports to validate death certificates for statistical tabulation of the occurrence rates of individual diseases." It is known that the error rate of death certificates can be high for certain diseases.
Rosenblatt's group'26' compared the clinical diagnosis of 139 lung cancers with the autopsy reports. In the latter case, only 27 cases were confirmed, an accuracy of about 20%. In considering the commonly used criterion for statistical significance ( p < 0.05), spurious positive associations are to be expected at a rate of 1 in 20.
It often happens that there are many epidemiological studies associating a number of different exposures with one cancer entity. As an example, Matanoski and Elliott'27' have listed the "classical" agents associated with bladder cancer in humans. Included are P-naphthylamine, sugar substitutes, hair dyes, etc. Since 1981, further epidemiological studies have been published associating more than 15 chemicals or occupational exposures with human bladder cancer ( Table 5) . (This does not mean that there cannot be more than one cause, but can all possible associations be true causes?)
ON ANIMAL EXPERIMENTS
If we reject the notion that epidemiological findings pinpoint the cause of human cancer, can we now decide that if an agent induces tumors in animals it is proved to cause human cancer? Are all animal carcinogens suspect human carcinogens regardless of the technique used to induce the cancer in the experimental animal? Like interpretations of epidemiological studies, too many global conclusions have been drawn from data generated from bioassays without critically evaluating the validity of those assays. From experience we know that too many published studies are flawed as a result, it is now possible to "prove" that a chemical is or is not an animal carcinogen.
Ame~'~') remarked that some chemicals given at the maximum tolerated dose (MTD) will lead to cell proliferation and inflammatory reactions. As a result, a high percentage of these natural and manmade chemicals will be classified as carcinogens! "More than 50 percent of the chemicals tested to date in rats and mice have been found to be carcinogens at the high doses admini~tered".(~') (Would this be the case if this same dose level were administered to humans?) H a~e m a n '~~' stated that if the animal dose was as low as 50% of the MTD, the carcinogenic action would have been missed. Dose-response is an important factor in concluding if an agent is an animal carcinogen, but this is not always stated or, apparently, recognized.
There are some major problems in interpreting information about animal carcinogens. One is that too many publications, especially those on risk assessment, have based their calculations on the data published without a critical appraisal of how that experiment was conducted. Many mathematical models have been formulated, and many statistical evaluations have been calculated, relating the animal data with expected rates of human cancer if *I recall in the 1930s and 1940s during our search for anti-TB drugs, that if a patient died in the hospital with any type of lung congestion, the death certificate would read, "tuberculosis" without regard to the true nature of that death.
FURST administered to humans at that level or dose. The use of flawed data, especially in quantitative risk assessments, and in spite of the sophistication of the mathematical models, have produced less than robust information.
Did someone once say "garbage in, garbage out"? or shall we say "garbage in, gossip out"?
None of these publications has raised the question, are these data from valid animal studies; was, for example, the route of administration rational? The lack of inquiry as to how the bioassay was conducted and the acceptance of the formation of a tumor by any means is surprising. Perhaps some authors have accepted the simplistic definition of a carcinogen as given above by Zwickey and Davis,(*) or even a later definition given by the IARC monographs from volume 17 on, which is:
The widely accepted meaning of the term "chemical carcinogen" and that used in these monographs is induction by chemicals of neoplasms that are not usually observed, the earlier induction by chemicals of neoplasms usually observed and/or the induction by chemicals of more neoplasms than are usually found-although fundamentally different mechanisms may be involved in these three phenomena.
Even many experienced experimentalists, when evaluating other published data, seldom consider the relevance of the route of administration, or the nature of the agent tested, but only the conclusions. At the present time, there are more than 300 chemicals listed as being "carcinogenic to animals." The fact is that the decision to classify these chemicals as animal carcinogens hides the enormous diversity of experimental conditions which generated the information. Some agents are active in only one species, or if administered by a special route, and sometimes only if the agent under test is dissolved or suspended in a special but not in a general vehicle. Gregory(44) states strongly, that "some species and strains of experimental animals have such unique mechanisms of developing cancer that the extrapolation of such bioassay results to the human situation would be fraudulent."
What is somewhat surprising is that only recently have experimentalists questioned the way chemicals have been tested for carcinogenicity; Roe(45) has been one of the few persistent critics.
PITFALLS IN EVALUATION
How relevant to human cancer is an agent that induces a cancer in an animal gland that has no counterpart in humans (i.e., the Zymbal gland). How does one relate the induction of a renal tumor in a rat by a mechanism that requires the presence of alpha,-microglobulin, a protein not found in humans?
How should one interpret information from a carcinogenic bioassay if by that special technique 90+ percent of the tested materials give positive results?
For example, if the Stanton technique is employed (wherein a fiber with specific dimensions is suspended in a beeswax-trioctanoin matrix and injected directly into the pleural cavity), over 90% of the fibers tested (regardless of the chemical composition) will induce mesotheliomas. Unfortunately, when this technique is used, selective conclusions are often made; aluminum oxide needles, glass fibers, and asbestos fibers are all positive. In publications that use generic terminology, both glass and asbestos are deemed carcinogenic, and exposure to these two agents is associated with the induction of mesotheliomas; for some unknown reason, aluminum is not included in this classification.
Another example is the employment of the Oppenheimer technique by which a solid piece of material such as a metal foil or plastic with a smooth surface is implanted under the skin of a rat. The vast majority of materials implanted this way will induce a fibrosarcoma at the site (metastases to the lungs are often noted in these experiments). Foils of both silver and aluminum test positive; some publications call silver carcinogenic(46' but not aluminum! This phenomenon is now called solid-state or foreign body carcinogenesis. So many substances are positive when tested by this technique, it is difficult to see how any extrapolations to humans can be made when a substance does induce a fibrosarcoma at the site of application.
F~rst'~') called attention to an unusual finding: occasionally when a metal or inorganic compound is tested for carcinogenicity by the intramuscular route, an osteogenic sarcoma appears in perhaps %oo rats under test. The induced cancer will often metastasize to the lungs, keeping its original histological character. This can happen whether or not the inorganic agent actually induces a fibrosarcoma at the site of injection. If the osteogenic sarcoma appears, should that agent be classified as a carcinogen?
Because of these observations, F~r s t '~~) cautioned against the use of the subcutaneous route in a bioassay to determine if a chemical is tumorigenic. Subsequently, the is^'^') checked the first 26 volumes of the IARC monographs and reported that only 50% of the agents which induced tumors by the subcutaneous route were active by any other route.
How does one interpret the appearance of a liver tumor after a halogenated organic compound is given at MTD in a single bolus by gavage using a vegetable oil vehicle, when no indication is given that the oil has been freed of oxidized impurities? What should be the interpretation if no liver tumor appears when an animal is given the same amount of the compound in the drinking water over a period of time? Certainly there is a difference in the concentrations and the duration of administration. Should not dose be factored in when extrapolations are made?
Is the induction of a liver tumor in the mouse an indication of the true carcinogenicity of the compound? Tomatis et concluded that there is a positive correlation between the ability of a compound to induce liver cell tumors, benign or malignant, in the mouse, and its capacity to induce tumors at any site in the rate or hamster. He reported that of 58 hepatocarcinogens for the mouse, 22 were active only in male mice, the others in both sexes. He reported that some of these compounds were also tested in rats and hamsters, and in the majority of these cases tumors were induced. He concludes by saying, '' neither does it imply that negative results in the mouse must be regarded as proof of safety." Roe,'50) on the other hand, concluded that data obtained from this mouse liver tumor model is not a reliable base for extrapolating the findings to humans.
Maronpot et a1.(5') analyzed in great detail the 278 two-year studies of the NTP program and concluded that for the study of potential liver tumor carcinogens, there is no good alternative to the use of the B6C3F1 mouse. They showed that there is no difference in the rate of appearance of hepatocellular carcinoma in these mice between cage controls, and those controls treated with corn oil by gavage; the approximate rates were 21 and 22%, respectively. Since corn oil can be a promoter and not a complete carcinogen, it is not surprising that the number of tumors in the vehicle controls was not higher compared with the untreated controls. * There is controversy over the significance of the use of gavage as a route of exposure. Perera et al. ,('*) list some factors which may affect the nature of the experiment; these include animal weight, age, and species. However, these factors may apply to any bioassay. More important factors will include the nature of the vegetable oil used, its purity, and whether or not the animal is fasted for 24 hours. They considered that gavage is an acceptable route after evaluating 117 agents from the NTP program. Twenty three agents were positive for tumor induction when administered by gavage. When 20 of these 23 were evaluated by another route, 19 were found active. (An analysis of their publication reveals that some of these agents given by other routes resulted in tumors different from those found following the use of gavage.)
Can a valid claim for carcinogenicity in a rodent be made if the compound when administered alone intratracheally induces no tumors, but when admixed with benzo(a)pyrene, does induce more tumors than did the hydrocarbon alone? F~r s t '~~) called the compound mixed with an aromatic hydrocarbon simply "a camer dust."
BIOASSAY S
There is no dearth of publications on the procedures for conducting a bioassay; in fact, whole books have been written on the subje~t.~'~~'') The guidelines of the National Cancer Institute''6) and those by Page'57) or Purchase('*) are very useful, but are not specific enough to help answer the question: Is it a human carcinogen'? *How many laboratories that use corn oil as the vehicle to dissolve or suspend the agent have tested that oil for oxidized impurities like eposides? How many laboratories have shaken vegetable oil vehicles with an aqueous iodide-iodine solution to remove oxidized products? Can the vegetable oils modify the outcome of a bioassay, for, are not fats and oils promoters? FURST Some suggestion^(^^.^) do come close to requiring specific conditions to be met in the animal bioassays so that the data generated can help answer the question. He does recommend realistic conditions for the animal experiments, including practical dose levels. Critics like Roe'45) still abound with objections to the way chemicals are tested for their potential carcinogenicity. He looks at parameters which can modify the outcome of a bioassay, these include such factors as hormone balance, other nongenotoxic parameters, diet restriction, and the duration of the experiment. However, specific directions for conducting the experiment are not given.
FACTORS FOR A VALID ANIMAL BIOASSAY
The ideal is to study humans for any condition which affects them. This is not possible, of course (Table 6 ). It is important to consider in some detail what are the factors which must be considered before a chemical can be established as an animal carcinogen in a valid study. This information would give the scientist a more robust basis for extrapolating these findings to humans. In my opinion, the strict criteria to be used in deciding on a valid bioassay are the following: 
The agent
The agent under consideration must be clearly and unequivocally defined. If it is a suspect human carcinogen, the agent must be identical to one to which a human is exposed.
Comments: Derivatives, metabolites, condensates other oxidation states, geometric isomers, components, or contaminants of the agent are not the agent. If a metabolic product of the agent is being tested, clear statements must be made to that effect. Is daminozide (alar) the "carcinogen" or is it the degraded product UDMH (unsymmetrkal dimethylhydrazine); is peanut butter the "carcinogen" or is it the contaminant aflatoxin? Exposure to nitropyrenes is not a substitute for gaseous diesel exhausts. Generic terms should not be. used; for instance chromium in place of chromate, or Cr(V1).
The test animal
The animal selected must be capable of developing the same histological type of cancer that is associated with human exposure to that defined agent.
Comments: The strain of animal selected should not have an unusually high rate of spontaneous tumors of the kind under investigation. Thus, the male Fischer 344 rat should not be used to study the induction of Leidig cell tumors of the testes by a suspect testicular carcinogen. The female C3H mouse must not be used if the induction of mammary carcinomas is the end point of the study. The arbitrary assignment of the inbred Fischer 344 rat, and the hybrid B6C3F1 (C57BL/6N X C3H/HeN) mouse is not indicated for each and every experiment.
The controls
It is essential to know the historical incidence and the type of spontaneous tumors in the test species selected. Cage and vehicle controls must be maintained along with the test animals, and must be assigned to the experiment at the same time as the treated groups.
Comments: By now there is sufficient published information to meet this requirement. For "controversial" agents, both a positive and a negative control should be employed. As an example, silver metal (and hence silver compounds) was a suspect animal carcinogen because the foil produced a fibrosarcoma at the subcutaneous implantation site when the Oppenheimer technique was used. We"') studied the ability of pure silver metal powder to induce fibrosarcomas in both sexes in the Fishcer 344 rats when the powder was suspended in an inert vehicle and injected intramuscularly. Both cage and vehicle controls were put on test at the same time. In addition, metallic gold powder was used as a negative control, whereas cadmium powder was the positive control. (Both of these control powders were tested previously in our laboratories.)
Neither gold nor silver powders induced tumors. Fibrosarcomas appeared in the cadmium-injected rats within a few weeks; and at the end of two years, the only fibrosarcomas detected were in the rats injected with the cadmium powder. Thus we concluded that silver was not to be considered an animal carcinogen, in spite of the fact that shiny silver foil did induce fibrosarcomas when administered by the Oppenheimer technique, namely, solid-state carcinogenesis.
The dose
The dose must include a realistic level that reflects that to which humans are likely to be exposed. Comments: Traditionally the maximum tolerated dose (MTD) is the highest dose administered in a bioassay. Many, but not all, experimenters also administer a fraction of that dose. A m d 4 " has noted that many agents given at the MTD will result in the induction of tumors: this phenomenon may not reflect the true carcinogenic potential of any substance. Previously, Ha~eman'~"recognized that there is no uniform agreement on what dose level should be established as the MTD. However, he stated that if one half of the MTD were administered in the NTP oral studies, two-thirds of the carcinogenic effect would have been missed. (No wonder there are more than 300+ compounds listed as animal carcinogens, but are they human carcinogens'?)
The route
The route of administration should be comparable or relevant to the human exposure. Comments: Certainly the experimenter, for various reasons, may use any route of exposure. To extrapolate findings using a route totally unrelated to human exposure appears to be of doubtful value. (At times the reason for using an unusual route like intrarenal, intracranial, intraorbital, is not at all apparent.)
To evaluate some agents to which humans are exposed by a totally different route seems irrelevant, e.g., feeding hair dyes, dosing the rat with benzene by gavage, injecting cis-platinum subcutaneously, skin painting of diesel fuel condensate.
Husbandry
Until quite recently, too little attention has been paid to this aspect in bioassay experiments. Comments: The literature is replete with publications showing the importance of animal room environment. Haseman et list a number of factors which may influence the tumor yield in a bioassay; included are lighting, ventilation, temperature, etc. However, in 1988, Haseman '62) concluded that the spontaneous tumor rate is not dependent on which shelf the animal cage is placed on the cage rack.
The spontaneous tumor rate can differ in the same strain, depending on whether the animals are housed singly or in groups, and their reaction to stress. Tumor incidence differences have been known to be related to the type of bedding used-hardwood shavings versus corn cob chips versus softwood shavings. Finally, major differences in tumor rates are recorded if animals are fed ad libitum, as opposed to using caloric re~triction.'~~.'~'
To assure the absence of acute toxicity in a bioassay, there are a number of parameters that are easily measured. These are animal weights, food and water intake, and later the results of histopathological evaluations. These are important aspects to help decide if the experiment is meaningful.
Duration of the bioassay
Experiments should be continued for the %fetime" of the animal. If possible, dosing should continue for at least two years. Some investigators suggest 18 months for mice and h a m~t e r s . (~'~~~'
Comments: Termination date can be determined when the expenment is being designed; the statistician can decide to terminate if an insufficient number of animals are alive at a given time. If the death rate is not too high, it is suggested that the experiment continue until the age of 104 weeks for the rat, 96 weeks for the mouse, and 80 weeks for the hamster.
FURST
There is an argument that for toxicity studies a year may be adequate. This is not true for a carcinogenesis bioassay. Since tumors usually appear late in life of both humans and animals, "lifetime" studies should be designed.
End points
There can be various end points to a bioassay. One of the most important is that the agent under test has induced a malignant cancer of the identical histological type at the same anatomical site as that found in the human when exposed to the suspect substance. (This is based on the assumption that the particular cancer is not normally found at a high rate in the test strain.)
Recently the definition of a carcinogen has been extended (see IARC definition'66') to include applied agents that result in the increase of tumors of any type, both benign and malignant over the controls. Also, if the lag time before the appearance of the tumors is decreased, the test agent is called a carcinogen. Another possible end point is the appearance of benign tumors not found in the controls.
Comments. The evaluation of these end points depends on the judgment of a pathologist who is versed in animal tumors; sometimes it may be necessary to employ other experts to help diagnose specific tumor types. (It is not unknown for pathologists to disagree with each other!)
The first end point, the determination that the growth is a true cancer, is most important in helping to relate that finding to answering the question, is it a human carcinogen?
For the experimenter, a set of criteria for determining if the induced growth is actually malignant includes the observation that the tumor does invade into other organs and, of course, the finding of metastatic lesions elsewhere in the animal body. Seldom used, but important, is a confirmatory test to help decide if the growth "induced' is a malignant cancer. The criterion for this is the ability of a growth to be transplanted in nonconditioned animals of the same species and strain for over three or more transplant generations retaining its original histological characteristics.
The statistical evaluation
It is axiomatic that a statistician must be involved with every phase of the experimental design, from the inception to the evaluation of the results. Are the number and nature of the tumors induced after exposure to the agent under test statistically different from those found (or expected) in the controls?
Comments. How important are historical tumor incidence values for the controls? How should one interpret the data from a bioassay if no cage control animal develops a single tumor, in spite of the fact that the strain used is especially bred to produce specific tumors at a specific site within a given time period? How does one interpret the appearance of one to three cancers of a given type in a test group of 50 animals and none in the controls, even though historical information reveals that a low incidence of that histological type in that strain is known? What should be the interpretation if only one or two treated animals develops tumors in a tissue or organ, in a strain that does not have a history of ever developing that tumor type spontaneously? Can one draw conclusions about the induction of a tumor type if the historical spontaneous incidence of that identical tumor type is very high? How significant is the number of animals with tumors versus the total number of tumors; can these data be extrapolated to the human condition?
The two extended definitions of a carcinogen, to wit, that (a) the latency period before the appearance of the tumors is shortened (although no new tumor types have been induced), must rely on a close inspection of the times of appearance of the tumors in both the controls and the treated animals. To obtain these data requires serial sacrifice to identify internal tumors, or continuous palpation to find "external" tumors. Extended definition (b) of a carcinogen is that following treatment there will be no shortening of the latent period before the appearance of the tumors, but at the end of the experiment more total tumors (benign and malignant) will appear in the treated animals relative to the controls.
To utilize these extended definitions will require expert statistical analysis and special guidance for interpretation. There have been cases where all the controls were sacrificed prior to the treated specimens; it is well known that the longer the animal lives, the greater the chance that spontaneous tumors will appear.
At present, there do not appear to be statistical guidelines for these two extended definitions of a carcinogen! Will data from these two types of experiments help answer our question? It must be realized that for many biological experiments replications will not be closer than 20 percent.
The replication
To be sure that the induced cancer in a particular strain of a species is not a case of species specificily, the experiment must be repeated in a different species.
Comments. Should replication be attempted by the same laboratory or a different one? However, there is no agreement in the scientific world that replication is essential.
The few chemicals that are accepted as human carcinogens do induce tumors in more than one species.'67' (It is surprising how few there are!) For those compounds found to be active in one species alone, some scientists believe that it is not necessary to use another species for verification.'68' Apparently there are some reviews in support of the hypothesis that one test species is adequate. Gold eta] . ,(69) using a select nonrandom group of chemicals report that for 392 chemicals tested in both rats and mice, 76% of the rat carcinogens are positive in mice, but only 709% of the mouse carcinogens are active in rats. They excluded some inorganic and polycyclic compounds, and only included the following routes in their analysis: drinking water, diet, gavage, inhalation and iv and ip injections. Haseman and HufC7" looked at 327 bioassays camed out by NCIINTP. (They concluded that only 266 studies were good enough to be included in their analysis.) They stated "the overall concordance between rats and mice exposed to the same chemical was 74 percent or 1981266." Purchase,'5x' on the other hand reported that of the 250 compounds listed by IARC, only 44% induced tumors in both mice and rats.
Certainly, it will save time and money if replication in another species is not required. The notion that there are species-specific unique mechanisms of developing tumors cannot be dismissed out of hand. '44' Although not a problem of trans-species extrapolation, another important consideration is the poor correlation of tumor induction when the two sexes are compared. Di car lo'^'^') analysis shows that only 21% of 221 substances tested were active in both sexes. If a chemical is active in only one species, or in only one sex, it would appear that extrapolation to humans would be tenuous. (Even the transplacental carcinogens affect both female and male offspring. )
OTHER FACTORS TO CONSIDER
Some years ago there was great interest and enthusiasm for short-term or genotoxic tests. Presently the importance of these tests seems to have diminished, but they still can provide corroborating information. However, many compounds, including the vast majority of inorganic agents, are not active in the mutagenic tests, unless the tests are tailormade for that specific inorganic agent. Also, a number of other animal carcinogens, such as hormones, asbestos, most metal ions, and carbon tetrachloride, fail to respond in an Ames test. Genotoxic tests have served a major purpose in that many general ideas about mutagenicity have been clarified. As a result, the modification of the DNA by an active agent is well established, and the structures of a number of adducts to guanine and adenine have been elucidated. La~ley'~') has reviewed the historical development and the usefulness of the relationship between mutagens and carcinogens. The publication by L i j i n~k y '~~) also dwells on the historical development of the relationship between mutagenicity and carcinogenicity; he also points out the shortcomings of the attempt to correlate the actions of the two disciplines and concludes that the relationship may be only coincidental. Since many human carcinogens may act by an epigenetic or nongenotoxic mechanism, the bacterial mutagenicity test, the most useful of all genotoxic tests, has limited value. (This does not mean no value.)
Probably one of the most important considerations is the similarity of the metabolism of the suspect carcinogenic compound in humans and in the experimental animal. If the test compound undergoes identical, or closely similar, biotransformations in both humans and in species used in the bioassay, and if the agent is shown to be carcinogenic in a valid animal experiment, more weight to consider the agent as a potential human carcinogen should be given.
QUESTIONS REMAIN
"Is it a human carcinogen?' The answer to that question is complex.
Seek simplicity and distrust it, The London branch of the Clairvoyant Society will not meet this Friday due to unforeseen circumstances.
The scientist cannot come to a definitive conclusion on the carcinogenic action of a substance in humans based on data from animal bioassays alone in the absence of epidemiological information! (Those involved in regulation have in the past set restrictions and standards based on results only from animal studies.) However, again, it must be emphasized that only valid animal studies should be considered.
Surprisingly few agents are well established as human carcinogens. And, of interest, many were identified by astute physicians before animal tests were conducted. Weisburger(6) reminds us that, ". . . most human carcinogens are also carcinogenic in animal models," and often the agent is active in more than one animal species. Weisburger and Williams (74) and Williams et al.@') list some of these culprits, and also present arguments in favor of relating experimental results alone with human cancer. They suggest, in the absence of epidemiological evidence, the chemical should be active in:
1. A variety of short-term tests, not just one, and are genotoxic 2. Several species, in high yields, with latent times of less than 18 months 3. Over a range of doses
The caveats should be that the exact agent (not with carrier dusts, or a derivative) is tested by a route of administration appropriate to human exposure. D~bing''~) also suggested guidance for decision making in case a new chemical is suspect, but there are no human studies on this compound. Higher incidence of total tumors and shorter latency periods before the tumors appear in the test animals are not sufficient criteria in themselves. Adequate numbers of experiments must be conducted using different routes and doses and more than one species. Perhaps it is time to decide what is "sufficient evidence" (IARC, 1985'")) for determining what chemical is an animal carcinogen rather than making the decision on minimum evidence.
MORE QUESTIONS AND SUGGESTIONS
These discussions may help establish what is a human carcinogen. But are they by themselves adequate? Are there not also human factors which eventually must be considered in the decision process? For example, of the hundreds of thousands of men exposed to asbestos dust in close quarters without adequate ventilation during World War 11, comparatively few have developed mesotheliomas. (For these it is certainly a tragedy.) Similarly, of the thousands of men exposed to vinyl chloride gas, relatively few have developed angiosarcoma of the liver. (Again, tragic for those who did.) Why so few? What is the difference between those who did develop cancer and those who did not?
To help conclude that a specific substance is a human carcinogen it is necessary to consider the following suggestions. As an absolute minimum, there should be a close agreement between conclusions from well-designed epidemiological studies of exposed populations, with conclusions drawn from good and valid animal bioassays (using appropriate routes of exposure and reasonable exposure levels and with an end point in which a cancer has been induced, one similar to that of the exposed human). Some corroboration from short-term tests will strengthen the association. If the biotransformation of the agent under consideration is similar in humans and one active animal species, there are more reasons to consider this agent a human carcinogen. The limitation is that the mechanism of action of the agent in inducing an animal cancer does not undergo a process or require an organ for which there is no human counterpart.
Cancer, however, is more complex than that. And there are real gaps in our knowledge about what is a realistic human carcinogen, and a number of publications have attempted to bridge this gap. Information from different species would be most useful. The validity of trans species extrapolation including Homo sapiens has not been adequately shown, in spite of tomes written on this. Coulston and S h~b i k '~~) attempted to relate human epidemiology and animal data to human carcinogens, however, only one chapter in their volume addresses the problem, and this only in general terms and concepts; no hard data on relationships are given. grass^'^^' does give 12 good examples where the two disciplines, epidemiology and experimental toxicology, complement one another. However, these examples are of the known compounds, those very few agents "accepted' to be human carcinogens. IARC Supplement #7f66) (a review of IARC monographs 1- 42, 1987 ) is a good source for comparing the conclusions of epidemiology with animal bioassays. One disturbing feature is that the IARC monographs, though permitted to do so, never seem to state "no evidence" for animal carcinogenicity: in the few cases where each and every animal experiment was negative, the statement is "insufficient evidence." Is this because of statistical limitations? Lifestyle of the human must be factored in. This feature apparently does not apply to animals; however, the restrictions under the way the animals are kept may constitute a parallelism. Diet must play a major role in considering who does and who does not develop cancer. The literature on this topic is unusually voluminous, and continues to grow daily. Some recent reviews are by Hayes and Campbell,f78) Palmer,(79) and Williams and Weisburger.(so) Although "diet, nutrition and cancer" is now a popular subject, interest in that subject goes back at least four decades."') However, only now are questions being asked of the cancer patient about the nature of the diet preceding the appearance of the cancer.
Will molecular mechanisms of carcinogene~is(*~-~~) as they are elucidated, help in the understanding of what is a human carcinogen? There are so many discrete steps in the formation of a cancer; many now can be identified, beside initiation and sets of promotion as well as progression.
Recently, Pitot(") listed the biological characteristics of each stage, and expanded upon the stage of progression. He noted that this was a distinct and final stage, and there was a demonstrable alteration in the cell genome. The transition between steps, as mentioned by Weinstein"" may be the result of different environments and biochemical events. Involved are activation of specific enzymes, and/or oncogenes, and not the least, translocations on chromosomes. Questions remain about the number of suppressor gene alleles that must be lost and from which chromosomal locations during the transition from a normal to a cancerous cell? This topic is well reviewed by Bouck and B e n t~n . "~) How fragile are the antioncogenes relative to the action of "carcinogens."
There is so much emphasis on the study of chemicals which induce cancer in animals yet the actual number of "established' human carcinogens@" is small relative to the vast array of chemicals to which the general population, and specifically those in the occupational setting, are exposed. May we suggest that more emphasis be placed on the neglected field of mechanisms of inhibition of carcinogenesis and m~tagenesis.@~) Are some selenium compounds true inhibitors of carcinogenesis? And what is the inhibitory role of DNA repair. Also, when molecular mechanisms are considered, more effort should be made to understand the epigenetic agents'") whose molecular pathways are yet to be elucidated; no doubt the identification of the macromolecules involved may or may not show parallelisms to the genotoxic agents.
An exogenous chemical agent cannot introduce new bases in the DNA (as can a virus). The chemical can only modify the genetic code by interaction with some moiety of DNA, thus distorting the function of normal cellular gene~.(~')This, of course, assumes that the DNA repair mechanism does not reverse this action. How should agents which do not follow a simple initiation-promotion sequence be treated?
Because of the very long latent time for the formation of most cancers in most humans, it is assumed that multiple cellular genes are required. Perhaps each is involved with a different mechanism. Where do these oncogenes and/or repressor genes (the number of synonyms for this last term is rapidly proliferating) fit into the p i~t u r e ? '~~.~~) Suggestions for research should include what is the complement of oncogenes carried normally by individuals. If a person does not carry one specific oncogene (or do we all?) and is exposed to a carcinogenic agent, will a cancer be induced? One day we will be able to screen people for their complete complement of oncogenes. (Then we will once again face a moral decision, should that person be told?)
Finally, when will be learn what roles heredity and genetics play in a human's susceptibility to develop when large groups of the population are exposed to the same agent? Will genetic predisposition become one of the most important factors for identifying persons at high risk for developing cancer?'96'
EPILOGUE
By no means should this essay be interpreted as saying or implying that precautions are not necessary; certainly exposure to any noxious or hazardous agent should be eliminated if possible, or minimized at least. No one is waiting around, as a cynic once said, "to count the bodies." However, the conclusion as to what is a human carcinogen cannot be made by simple associations, or by fiat. With all due respect to those who are involved in 13 Occurrence of common verses uncommon neoplasms 3. Progression from benign to malignant neoplasia as well as from preneoplasia to neoplastic lesions 4. That most benign neoplasms progress, although some have been shown to regress if exposure has been discontinued early enough; therefore, where there is no convincing evidence of regression, the most 5.
7.
8.
9.
10.
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prudent public health course is to believe that benign neoplasms have the potential to become malignant Combining benign and malignant neoplasiaof the same morphologic type known or thought to represent stages of progression in the same organ or tissue Latency in neoplastic induction Multiplicity in site-specific neoplasia Metastases Supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species) The presence or absence of dose-response relationships The concurrent control tumor incidence as well as historical control rate and variability for a specific neoplasm The statistical significance of the observed tumor increase Survival-adjusted analysis and false positive or false negative concerns Structure-activity correlations In some cases genetic toxicology Source: After Ra11. '97) regulation, it is still possible to raise the question, is it a human carcinogen? and to look at the problem from a scientific point of view. A number of scientists are now becoming concerned with this problem. Very conservative approaches to interpretation of available data may be in the public interest, but assumptions about the nature of the carcinogenic process must be made. Conclusions from the NIEHS/NTP program (Table 7) , though peer re~iewed,'~'' cannot, in all cases, be scientifically substantiated.
Higgin~on'~~) has best summarized the modern scientist's dilemma; he treated the limitations to epidemiology, the complex carcinogenic risk factors, and the individual susceptibility. He concluded that we must find means to interfere with the carcinogenic process. Is it not surprising that most of the authors voicing concern, as quoted in this essay, expressed these only in recent years?
As time goes on, our tools for investigating human carcinogens will become more sophisticated. It is too early to draw major conclusions from the data being generated from DNA and hemoglobin adducts. Are they really related to the first step, initiation? How stable are these adducts; what are their half-lives? What is the role of DNA repair in eradicating these adducts? Also, a comparison of DNA repair capacity in humans versus animals will aid our knowledge on the importance of these adducts in the carcinogenic process.
Emerging is an advance in epidemiology which will incorporate some of the new molecular biology. The discipline called molecular epidemiology (99) will include information from adducts, chromosome abnormalities, and somatic cell mutations. However, we still cannot overlook the fact that "molecular epidemiology may not overcome the subjective problems of conventional epidemiology. Eventually, environmental carcinogens may be interpreted from the human standpoint on a realistic basis.
Beyond this essay, there is one pious hope that in the future, the public will be better informed about the complexity of cancer; especially environmental cancer. Also, they should appreciate that there is no simple Pavlovian response, first a single exposure and shortly a cancer appears. For the general public, the mass media can be a great educational tool; unfortunately, the mass media too often alarms rather than alerts.
ACKNOWLEDGMENTS
I would like to acknowledge some of my colleagues who listened, but did not always agree while I discussed my ideas on this question. In this regard, Walter W. Weyzen, M.D., Ph.D., was especially helpful to me. 
